The investigation is certain to heighten concerns among other global drug makers, some of which are already under scrutiny from regulators in the United States and elsewhere over the incentives they give to doctors or clients.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.